Background
Removal of immunoglobulin free light chains (FLCs) by high cut-off haemodialysis (HCO-HD) has recently been described as a new treatment option for patients with biopsy-proven cast nephropathy, secondary to multiple myeloma [1] . In an uncontrolled pilot study, 14 of 19 patients with myeloma kidney and dialysis-dependent renal failure subsequently became independent of dialysis following treatment with HCO-HD and chemotherapy [2] . Two randomized controlled trials [EuLITE [3] and MYRE (NCT01208818)] are further evaluating this new treatment to determine if FLC removal by HCO-HD increases the rate of renal recovery. In parallel with these studies, the treatment continues to be used and evaluated by clinicians internationally. The purpose of the case reports presented here is to discuss why HCO-HD could not effectively remove FLCs in two patients.
Case reports

Case 1
A 63-year-old man presented with dysuria and rapidly progressive renal failure. On admission, his serum creatinine level was 150 μmol/L (1.69 mg/dL), haemoglobin 8 g/L, calcium 2.5 mmol/L and serum total protein 70 g/L. By Day 3, the serum creatinine had risen to 636 μmol/L (7.2 mg/dL). Serum protein electrophoresis (SPE) and subsequent immunofixation detected an IgA lambda monoclonal gammopathy [9. 68 g/L by SPE densitometry (SPED)] with lambda FLC (not quantifiable by SPED) and associated hypogammaglobulinaemia. Serum-free lambda light chain concentration was 7510 mg/L (Freelite; The Binding Site, Birmingham, UK). Bone marrow examination showed a clonal proliferation of plasma cells (10%) and a renal biopsy demonstrated cast nephropathy and 25% interstitial fibrosis.
A chemotherapy regime consisting of bortezomib and dexamethasone was commenced. Initially, standard haemodialysis was used to support the patient's renal failure and when myeloma kidney was diagnosed, protein permeable dialysis was initiated. Five single-dialyser 5-h sessions with the Toray BK-F (Toray Industries Inc., Tokyo, Japan) were followed by six single-dialyser 5-h sessions with the Gambro HCO 1100 (Gambro, Hechingen, Germany). Neither of these protein permeable dialysers reduced the serum FLC concentrations significantly, pre-and post-dialysis serum FLC levels, and mean FLC reductions per dialysis session were 7% (6900-6410 mg/L) and 7% (4130-3820 mg/L), respectively. Three months following treatment, the patient remained dialysis dependent.
Size-exclusion separation of the patient's sera detected lambda FLCs at three molecular weights: 50 kDa (dimer), 150-200 kDa and >200 kDa ( Figure 1a ). Western blot evaluation of these fractions confirmed the presence of lambda FLC with no intact immunoglobulin (data not shown). Nephelometric results suggested that lambda dimers accounted for 9% of the lambda FLCs present in the patient's sera; the remaining FLCs consisted of higher polymers.
Case 2
A 51-year-old woman with multiple myeloma, producing monoclonal IgG kappa (32.9 g/L SPED) and kappa FLC (<1 g/L SPED), presented with rapidly progressive renal failure. The patient had initially been diagnosed 9 years previously and had received multiple lines of treatment (including allogeneic transplant). Following a further relapse, 2 days into a new bortezomib-based treatment course, she developed severe gastroenteritis and secondary dehydration. At this stage, her serum creatinine increased from a baseline of 114 μmol/L (1.3 mg/dL) to 492 μmol/L (5.5 mg/dL); serum calcium was 2.6 mmol/L. Following rehydration, the patient remained in severe renal failure with a serum creatinine of 631 μmol/L (7.1 mg/dL). The serum kappa FLC concentration was 7280 mg/L. HCO-HD was commenced using the Gambro HCO 1100 dialyser. Dialysis sessions were of 6-h duration using two HCO 1100 dialysers in series. The mean reduction in serum kappa FLCs over five HCO-HD sessions was 10.5% (range 0-18%) with a median clearance rate of 2.9 mL/min (range 0.8-12.6). Size-exclusion separation of the patient's sera, as described above, detected kappa FLCs at three molecular weights: 25 kDa (monomer), 50 kDa (dimer) and a broad band of activity at >100 kDa (Figure 1b) . Western blot analysis confirmed the presence of kappa FLCs in these fractions with no intact immunoglobulin (data not shown). Nephelometric measurements indicated that kappa monomers accounted for 10% of the FLCs present in the patient's sera, dimers a further 10% with the remainder present as higher polymers. Analysis of dialysate fluid, from HCO-HD sessions, demonstrated only kappa monomers (25 kDa).
Control patients
HCO-HD usually results in median serum FLC reductions of 60-70% for kappa and lambda FLCs [7] . Typically, kappa FLCs are present in the sera as monomers and lambda as dimers. Figure 1 demonstrates the presence of lambda dimers (Figure 1a , black line) and kappa monomers (Figure 1b , black line) from two patients with biopsy-proven cast nephropathy who had significant reductions in serum FLCs with HCO-HD. No larger polymers were detected in these patients' sera.
Discussion
Serum concentrations of monoclonal FLCs can be several thousand times above normal in patients with severe renal failure secondary to multiple myeloma [4] . When reversible factors, such as hypercalcaemia and dehydration, have been excluded, the cause of renal failure in the majority of patients is myeloma kidney (cast nephropathy), a direct consequence of the high serum FLC concentrations. For this reason, treatment strategies have been directed towards achieving a rapid reduction in the serum FLC concentrations. This strategy is supported by the results of a study by Leung et al. [5] , who identified that patients with cast nephropathy recovered renal function when a reduction in serum FLCs of >50% was achieved. To enable this reduction, effective chemotherapy is required to decrease the FLC production rate by the plasma cell clone. In addition, the direct removal of FLCs from the serum can be used as an adjuvant treatment. Historically, plasma exchange has been employed for this purpose, although the results of the most robust clinical trial to date showed no benefit [6] .
Extended HCO-HD has been described as an alternative strategy to plasma exchange for rapidly removing large quantities of serum FLCs. Clearance rates of 30-40 mL/ min for both kappa and lambda FLCs are typical, with associated reductions in serum concentrations of 60-70% per session [7] . Evaluation of the sera of patients in whom extended HCO-HD successfully removed FLCs demonstrated that the FLCs present were below the molecular weight cut-off of the HCO membrane ( Figure 1 ). The two cases reported here are the first to describe patients in whom HCO-HD did not result in effective removal of FLCs. In both patients, size exclusion chromatography identified the presence of large polymers. The molecular weight of these large polymers exceeded the effective cut-off of the dialyser therefore limiting their removal.
Analysis of serum FLCs allows same-day reporting of results, enabling clinicians to rapidly identify patients in whom HCO-HD does not effectively remove FLCs. Size exclusion chromatography can then be used to confirm the presence of the large polymers. However, given the limited availability and prolonged analysis time of size exclusion chromatography, an alternative method would be to analyse the FLC concentration in the dialysate and calculate the FLC clearance rate.
It should be noted that measurement of polymerized FLC is unlikely to be completely accurate. The presence of polymers accelerates nephelometric reactions so the amount of polymerized FLC is likely to be overestimated when compared to the unpolymerized calibrator [8, 9] . Conversely, the presence of different-sized polymers will prevent the formation of focused protein bands by SPE, so densitometry will tend to underestimate the amount of monoclonal protein present [10] . Therefore, it is unsurprising that measurement by nephelometry and SPED are frequently discrepant.
Aggregation of serum FLCs has previously been reported [11, 12] . Although the incidence of large FLC polymers in patients with multiple myeloma and renal failure is believed to be low, the precise incidence is not known. Of interest, the first patient had a renal biopsy that demonstrated cast nephropathy, suggesting that the polymerization of the FLCs may be a transient process depending on factors such as absolute serum concentrations and hydration status. Potentially, plasma exchange could have a role in the management of these patients by removing the large polymers.
In summary, we present the analysis of two patients with severe renal failure and multiple myeloma in whom HCO-HD did not effectively remove their monoclonal FLCs. Analysis of their serum indicated that significant proportions of their tumour-produced FLC were in the form of polymers too large to pass through the dialysis membrane.
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